ImmunoGen News

ImmunoGen Inc. is going to be a very essential player in the biotech sector in the near future.

ImmunoGen, Inc. , a biotechnology company that develops anticancer therapeutics using its Targeted Antibody Payload antibody-drug conjugate technology, today announced that Gregory Perry, Executive Vice President and Chief Financial Officer, will present at the upcoming Credit Suisse Antibody Day in New York.

Jackpotpennystocks.com , an investor research portal specializing in several sectors including biotech and healthcare and tech stocks on the U.S. market, issues news updates on the following stock:- ImmunoGen, Inc.

ImmunoGen issued its quarterly earnings data on Friday. The company reported earnings per share for the quarter, beating the analysts' consensus estimate of by $0.13, Analyst Ratings.Net reports.

"Based on published clinical findings and patient anecdotes, we believe Kadcyla will make a notable difference for many patients and become a highly successful product," commented Daniel Junius, President and CEO.

"Based on published clinical findings and patient anecdotes, we believe Kadcyla will make a notable difference for many patients and become a highly successful product," commented Daniel Junius, President and CEO.